Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81449174 | 8144917 | 4 | F | 20160521 | 20160822 | 20110920 | 20160824 | EXP | PHHY2011CA82381 | NOVARTIS | 63.40 | YR | M | Y | 0.00000 | 20160825 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 81449174 | 8144917 | 1 | PS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 20 MG, QMO (EVERY 4 WEEKS) | 21008 | 20 | MG | SUSPENSION | /month | ||||||
| 81449174 | 8144917 | 2 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 20 MG, QMO (ONCE A MONTH) | 21008 | 20 | MG | SUSPENSION | /month | ||||||
| 81449174 | 8144917 | 3 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO (ONCE A MONTH) | 21008 | 30 | MG | SUSPENSION | /month | ||||||
| 81449174 | 8144917 | 4 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 60 MG, QMO (ONCE A MONTH) | 21008 | 60 | MG | SUSPENSION | /month | ||||||
| 81449174 | 8144917 | 5 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO (ONCE A MONTH) | 21008 | 30 | MG | SUSPENSION | /month | ||||||
| 81449174 | 8144917 | 6 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 40 MG, QMO (ONCE A MONTH) | 21008 | 40 | MG | SUSPENSION | /month | ||||||
| 81449174 | 8144917 | 7 | C | CLOMIPRAMINE | CLOMIPRAMINE | 1 | Unknown | 3 DF, | 0 | 3 | DF | TABLET | |||||||
| 81449174 | 8144917 | 8 | C | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 81449174 | 8144917 | 1 | Carcinoid tumour |
| 81449174 | 8144917 | 7 | Product used for unknown indication |
| 81449174 | 8144917 | 8 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 81449174 | 8144917 | OT |
| 81449174 | 8144917 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 81449174 | 8144917 | Blood count abnormal | |
| 81449174 | 8144917 | Blood potassium decreased | |
| 81449174 | 8144917 | Condition aggravated | |
| 81449174 | 8144917 | Death | |
| 81449174 | 8144917 | Fatigue | |
| 81449174 | 8144917 | Gait disturbance | |
| 81449174 | 8144917 | Limb discomfort | |
| 81449174 | 8144917 | Malaise | |
| 81449174 | 8144917 | Malignant neoplasm progression | |
| 81449174 | 8144917 | Nausea | |
| 81449174 | 8144917 | Neoplasm recurrence | |
| 81449174 | 8144917 | Nervousness | |
| 81449174 | 8144917 | Pain in extremity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 81449174 | 8144917 | 1 | 20070315 | 2008 | 0 | |
| 81449174 | 8144917 | 2 | 2008 | 2011 | 0 | |
| 81449174 | 8144917 | 3 | 2011 | 2012 | 0 | |
| 81449174 | 8144917 | 4 | 2012 | 2012 | 0 | |
| 81449174 | 8144917 | 5 | 2012 | 2015 | 0 | |
| 81449174 | 8144917 | 6 | 2015 | 2016 | 0 |